Invivyd (NASDAQ:IVVD) Upgraded at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of Invivyd (NASDAQ:IVVD) to a strong-buy rating in a research note published on Wednesday morning, Zacks.com reports.

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Invivyd in a research note on Tuesday.

Invivyd Stock Performance

NASDAQ IVVD opened at $0.91 on Wednesday. Invivyd has a twelve month low of $0.81 and a twelve month high of $5.20. The stock has a market cap of $109.12 million, a price-to-earnings ratio of -0.50 and a beta of 0.63. The firm’s 50 day moving average price is $0.99 and its two-hundred day moving average price is $1.39.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.03). The business had revenue of $2.26 million for the quarter, compared to analysts’ expectations of $4.91 million. On average, research analysts forecast that Invivyd will post -0.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Invivyd

A number of institutional investors have recently modified their holdings of the stock. Chase Investment Counsel Corp acquired a new stake in shares of Invivyd in the 1st quarter valued at $271,000. SG Americas Securities LLC acquired a new stake in shares of Invivyd in the 1st quarter valued at $56,000. Vanguard Group Inc. lifted its stake in shares of Invivyd by 3.9% in the 1st quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock valued at $11,594,000 after purchasing an additional 97,496 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Invivyd in the 1st quarter valued at $905,000. Finally, Jacobs Levy Equity Management Inc. lifted its stake in shares of Invivyd by 21.7% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 435,338 shares of the company’s stock valued at $1,933,000 after purchasing an additional 77,603 shares during the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.